aluates Reports

$ 0.0

Automative

Global PD-1 and PD-L1 Monoclonal Antibody Market Research Report 2025

Published Date: 2025-12-26

Report Code: QYRE-Auto-21I10213

Global PD 1 and PD L1 Monoclonal Antibody Market Research Report 2022

BUY CHAPTERS

Global PD-1 and PD-L1 Monoclonal Antibody Market Research Report 2025

Code: QYRE-Auto-21I10213

Report

2025-12-26

Pages:122

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Merk

Bristol Myers Squibb Company

Roche

Pfizer Inc

Astrazeneca plc

Junshi Biosciences

Innovent

Hengrui

BeiGene Ltd

ALPHAMAB ONCOLOGY

Akeso, Inc.

Cstone

Henlius Biotech

Lepu Biopharma

PD-1 and PD-L1 Monoclonal Antibody Market Size

The global market for PD-1 and PD-L1 Monoclonal Antibody was valued at US$ 52985 million in the year 2024 and is projected to reach a revised size of US$ 109949 million by 2031, growing at a CAGR of 11.2% during the forecast period.

PD-1 and PD-L1 Monoclonal Antibody Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on PD-1 and PD-L1 Monoclonal Antibody competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

PD-1 and PD-L1 monoclonal antibodies are therapeutic antibodies designed to restore T-cell–mediated antitumor immunity by blocking the immune checkpoint pathway exploited by tumors, addressing the limitations of conventional chemotherapy and targeted therapies in advanced solid tumors, including insufficient response durability, high toxicity, and acquired resistance. Originating from discoveries in the 1990s that identified PD-1 and PD-L1 as key regulators of tumor-induced immune suppression, researchers engineered monoclonal antibodies capable of disrupting this pathway, leading to the approval of the first agents in 2014 and reshaping the global oncology landscape. Their development and manufacturing rely on a sophisticated upstream biopharmaceutical ecosystem encompassing nucleic acid materials for cell line engineering, expression vectors, mammalian cell culture media, bioreactors, chromatography resins, filtration consumables, aseptic filling components, and analytical instruments, all of which ensure structural integrity, batch consistency, and clinical reliability of the final antibody products.In 2024, global sales of PD-1 and PD-L1 monoclonal antibodies reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.

From a market standpoint, PD-1 and PD-L1 monoclonal antibodies have evolved from a landscape dominated by a few originator products to one characterized by broad participation, rapid indication expansion, and growing adoption across diverse clinical settings. Clinical guidelines worldwide increasingly position these therapies as standard options in major tumor types, with use extending from late-stage treatment into adjuvant and neoadjuvant settings. The emergence of biosimilars and expanding access in emerging markets further reshape the competitive environment, creating a multi-tiered market where originator drugs, improved formulations, and domestically developed innovations coexist.

Looking ahead, differentiation and combination strategies will define the next stage of development. Companies are pursuing engineered antibodies with enhanced affinity, reduced immunogenicity, and more convenient administration profiles, while combination regimens with immunomodulators, targeted agents, cell therapies, radiotherapy, or chemotherapy aim to expand responder populations and delay resistance. Advances in companion diagnostics, biomarker stratification, and functional imaging will enhance precision in patient selection, driving the market toward more tailored, combination-based, and long-term treatment paradigms.

Key growth drivers include persistent unmet clinical needs, strong demand in high-mortality cancers, supportive regulatory frameworks for innovative immunotherapies, sustained investment in biopharmaceutical R&D, and increasing clinical experience at treatment centers. In parallel, maturing supply chains, rising localization of critical raw materials, and expanded manufacturing capacity provide structural support for continued market expansion. Ecosystem players such as CROs, CDMOs, and diagnostic developers further accelerate innovation by reducing development barriers and enabling faster iteration.

However, the field faces notable constraints. Response rates remain suboptimal in several tumor types, and resistance mechanisms—both intrinsic and acquired—limit therapeutic durability. High treatment costs and variability in reimbursement policies contribute to uneven access, particularly in developing regions, while intensifying market competition exerts pricing pressure and compresses margins. Moreover, the inherent technical complexity of biologics manufacturing and the stringent requirements for batch consistency pose challenges for new entrants. The pace of future growth will depend on scientific breakthroughs, payer policy evolution, and the accumulation of real-world evidence that validates long-term clinical value.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Monoclonal Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Monoclonal Antibody.

The PD-1 and PD-L1 Monoclonal Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-1 and PD-L1 Monoclonal Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, by Product Name and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the PD-1 and PD-L1 Monoclonal Antibody manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Product Name and by regions.

Scope of PD-1 and PD-L1 Monoclonal Antibody Market Report

Report Metric	Details
Report Name	PD-1 and PD-L1 Monoclonal Antibody Market
Accounted market size in year	US$ 52985 million
Forecasted market size in 2031	US$ 109949 million
CAGR	11.2%
Base Year	year
Forecasted years	2026 - 2031
Segment by Type	PD-1 PD-L1
Segment by Product Name	Pembrolizumab Nivolumab Cemiplimab Toripalimab Sintilimab Tislelizumab Camrelizumab Penpulimab Retifanlimab Others
Segment by Dosage Strength	100 mg / Vial 200 mg / Vial 240 mg / Vial 300 mg / Vial
Segment by Application	Solid Tumors Blood-related Tumors
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merk, Bristol-Myers Squibb Company, Roche, Pfizer, AstraZeneca, Junshi Biosciences, Innovent, Hengrui, BeiGene, Alphamab Oncology, Cstone, Akeso, Henlius Biotech, Lepu Biopharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1 and PD-L1 Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1 and PD-L1 Monoclonal Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is PD-1 and PD-L1 Monoclonal Antibody Market growing?

Ans: The PD-1 and PD-L1 Monoclonal Antibody Market witnessing a CAGR of 11.2% during the forecast period 2026-2031.

What is the PD-1 and PD-L1 Monoclonal Antibody Market size in 2031?

Ans: The PD-1 and PD-L1 Monoclonal Antibody Market size in 2031 will be US$ 109949 million.

What is the PD-1 and PD-L1 Monoclonal Antibody Market share by type?

Ans: In 2024, global sales of PD-1 and PD-L1 monoclonal antibodies reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.

Who are the main players in the PD-1 and PD-L1 Monoclonal Antibody Market report?

Ans: The main players in the PD-1 and PD-L1 Monoclonal Antibody Market are Merk, Bristol-Myers Squibb Company, Roche, Pfizer, AstraZeneca, Junshi Biosciences, Innovent, Hengrui, BeiGene, Alphamab Oncology, Cstone, Akeso, Henlius Biotech, Lepu Biopharma

What are the Application segmentation covered in the PD-1 and PD-L1 Monoclonal Antibody Market report?

Ans: The Applications covered in the PD-1 and PD-L1 Monoclonal Antibody Market report are Solid Tumors, Blood-related Tumors

What are the Type segmentation covered in the PD-1 and PD-L1 Monoclonal Antibody Market report?

Ans: The Types covered in the PD-1 and PD-L1 Monoclonal Antibody Market report are PD-1, PD-L1

1 PD-1 and PD-L1 Monoclonal Antibody Market Overview

1.1 Product Definition

1.2 PD-1 and PD-L1 Monoclonal Antibody by Type

1.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Type (2024 VS 2031)

1.2.2 PD-1

1.2.3 PD-L1

1.3 PD-1 and PD-L1 Monoclonal Antibody by Product Name

1.3.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Product Name: 2024 VS 2031

1.3.2 Pembrolizumab

1.3.3 Nivolumab

1.3.4 Cemiplimab

1.3.5 Toripalimab

1.3.6 Sintilimab

1.3.7 Tislelizumab

1.3.8 Camrelizumab

1.3.9 Penpulimab

1.3.10 Retifanlimab

1.4 PD-1 and PD-L1 Monoclonal Antibody by Dosage Strength

1.4.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Dosage Strength: 2024 VS 2031

1.4.2 100 mg / Vial

1.4.3 200 mg / Vial

1.4.4 240 mg / Vial

1.4.5 300 mg / Vial

1.5 PD-1 and PD-L1 Monoclonal Antibody by Application

1.5.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Application (2024 VS 2031)

1.5.2 Solid Tumors

1.5.3 Blood-related Tumors

1.6 Global PD-1 and PD-L1 Monoclonal Antibody Market Size Estimates and Forecasts

1.6.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue 2020-2031

1.6.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales 2020-2031

1.6.3 Global PD-1 and PD-L1 Monoclonal Antibody Market Average Price (2020-2031)

1.7 Assumptions and Limitations

2 PD-1 and PD-L1 Monoclonal Antibody Market Competition by Manufacturers

2.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Manufacturers (2020-2025)

2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Manufacturers (2020-2025)

2.3 Global PD-1 and PD-L1 Monoclonal Antibody Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of PD-1 and PD-L1 Monoclonal Antibody, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Product Type & Application

2.7 Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Date of Enter into This Industry

2.8 Global PD-1 and PD-L1 Monoclonal Antibody Market Competitive Situation and Trends

2.8.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Concentration Rate

2.8.2 The Global 5 and 10 Largest PD-1 and PD-L1 Monoclonal Antibody Players Market Share by Revenue

2.8.3 Global PD-1 and PD-L1 Monoclonal Antibody Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global PD-1 and PD-L1 Monoclonal Antibody Market Scenario by Region

3.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region: 2020-2031

3.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region: 2020-2025

3.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region: 2026-2031

3.3 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2020-2031

3.3.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2020-2025

3.3.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2026-2031

3.4 North America PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country

3.4.1 North America PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2031)

3.4.3 North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country

3.5.1 Europe PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2031)

3.5.3 Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Region

3.6.1 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2020-2031)

3.6.3 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country

3.7.1 Latin America PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2031)

3.7.3 Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country

3.8.1 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2031)

3.8.3 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2020-2031)

4.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2020-2025)

4.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2026-2031)

4.1.3 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2020-2031)

4.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2020-2031)

4.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2020-2025)

4.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2026-2031)

4.2.3 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2020-2031)

4.3 Global PD-1 and PD-L1 Monoclonal Antibody Price by Type (2020-2031)

5 Segment by Application

5.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2020-2031)

5.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2020-2025)

5.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2026-2031)

5.1.3 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2020-2031)

5.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2020-2031)

5.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2020-2025)

5.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2026-2031)

5.2.3 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2020-2031)

5.3 Global PD-1 and PD-L1 Monoclonal Antibody Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merk

6.1.1 Merk Company Information

6.1.2 Merk Description and Business Overview

6.1.3 Merk PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merk PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.1.5 Merk Recent Developments/Updates

6.2 Bristol-Myers Squibb Company

6.2.1 Bristol-Myers Squibb Company Company Information

6.2.2 Bristol-Myers Squibb Company Description and Business Overview

6.2.3 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates

6.3 Roche

6.3.1 Roche Company Information

6.3.2 Roche Description and Business Overview

6.3.3 Roche PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Roche PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.3.5 Roche Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Company Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Pfizer PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 AstraZeneca

6.5.1 AstraZeneca Company Information

6.5.2 AstraZeneca Description and Business Overview

6.5.3 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.5.4 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.5.5 AstraZeneca Recent Developments/Updates

6.6 Junshi Biosciences

6.6.1 Junshi Biosciences Company Information

6.6.2 Junshi Biosciences Description and Business Overview

6.6.3 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.6.5 Junshi Biosciences Recent Developments/Updates

6.7 Innovent

6.7.1 Innovent Company Information

6.7.2 Innovent Description and Business Overview

6.7.3 Innovent PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Innovent PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.7.5 Innovent Recent Developments/Updates

6.8 Hengrui

6.8.1 Hengrui Company Information

6.8.2 Hengrui Description and Business Overview

6.8.3 Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Hengrui PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.8.5 Hengrui Recent Developments/Updates

6.9 BeiGene

6.9.1 BeiGene Company Information

6.9.2 BeiGene Description and Business Overview

6.9.3 BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.9.4 BeiGene PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.9.5 BeiGene Recent Developments/Updates

6.10 Alphamab Oncology

6.10.1 Alphamab Oncology Company Information

6.10.2 Alphamab Oncology Description and Business Overview

6.10.3 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.10.5 Alphamab Oncology Recent Developments/Updates

6.11 Cstone

6.11.1 Cstone Company Information

6.11.2 Cstone Description and Business Overview

6.11.3 Cstone PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Cstone PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.11.5 Cstone Recent Developments/Updates

6.12 Akeso

6.12.1 Akeso Company Information

6.12.2 Akeso Description and Business Overview

6.12.3 Akeso PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Akeso PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.12.5 Akeso Recent Developments/Updates

6.13 Henlius Biotech

6.13.1 Henlius Biotech Company Information

6.13.2 Henlius Biotech Description and Business Overview

6.13.3 Henlius Biotech PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Henlius Biotech PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.13.5 Henlius Biotech Recent Developments/Updates

6.14 Lepu Biopharma

6.14.1 Lepu Biopharma Company Information

6.14.2 Lepu Biopharma Description and Business Overview

6.14.3 Lepu Biopharma PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Lepu Biopharma PD-1 and PD-L1 Monoclonal Antibody Product Portfolio

6.14.5 Lepu Biopharma Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 PD-1 and PD-L1 Monoclonal Antibody Industry Chain Analysis

7.2 PD-1 and PD-L1 Monoclonal Antibody Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 PD-1 and PD-L1 Monoclonal Antibody Production Mode & Process Analysis

7.4 PD-1 and PD-L1 Monoclonal Antibody Sales and Marketing

7.4.1 PD-1 and PD-L1 Monoclonal Antibody Sales Channels

7.4.2 PD-1 and PD-L1 Monoclonal Antibody Distributors

7.5 PD-1 and PD-L1 Monoclonal Antibody Customer Analysis

8 PD-1 and PD-L1 Monoclonal Antibody Market Dynamics

8.1 PD-1 and PD-L1 Monoclonal Antibody Industry Trends

8.2 PD-1 and PD-L1 Monoclonal Antibody Market Drivers

8.3 PD-1 and PD-L1 Monoclonal Antibody Market Challenges

8.4 PD-1 and PD-L1 Monoclonal Antibody Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Merk

Bristol Myers Squibb Company

Roche

Pfizer Inc

Astrazeneca plc

Junshi Biosciences

Innovent

Hengrui

BeiGene Ltd

ALPHAMAB ONCOLOGY

Akeso, Inc.

Cstone

Henlius Biotech

Lepu Biopharma

List of Tables

Table 1. Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Product Name, (US$ Million) & (2024 VS 2031)

Table 3. Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Dosage Strength, (US$ Million) & (2024 VS 2031)

Table 4. Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Application (2024 VS 2031) & (US$ Million)

Table 5. Global PD-1 and PD-L1 Monoclonal Antibody Market Competitive Situation by Manufacturers in 2024

Table 6. Global PD-1 and PD-L1 Monoclonal Antibody Sales (K Units) of Key Manufacturers (2020-2025)

Table 7. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Manufacturers (2020-2025)

Table 8. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Manufacturers (2020-2025)

Table 9. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Share by Manufacturers (2020-2025)

Table 10. Global Market PD-1 and PD-L1 Monoclonal Antibody Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 11. Global Key Players of PD-1 and PD-L1 Monoclonal Antibody, Industry Ranking, 2022 VS 2023 VS 2024

Table 12. Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Manufacturing Sites & Headquarters

Table 13. Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Product Type & Application

Table 14. Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Date of Enter into This Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global PD-1 and PD-L1 Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Monoclonal Antibody as of 2024)

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global PD-1 and PD-L1 Monoclonal Antibody Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2020-2025) & (K Units)

Table 20. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2020-2025)

Table 21. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2026-2031) & (K Units)

Table 22. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2026-2031)

Table 23. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)

Table 24. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2020-2025)

Table 25. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)

Table 26. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2026-2031)

Table 27. North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. North America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2025) & (K Units)

Table 29. North America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2026-2031) & (K Units)

Table 30. North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)

Table 31. North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)

Table 32. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 33. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2025) & (K Units)

Table 34. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2026-2031) & (K Units)

Table 35. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)

Table 36. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)

Table 37. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 38. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2020-2025) & (K Units)

Table 39. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2026-2031) & (K Units)

Table 40. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)

Table 41. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)

Table 42. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Latin America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2025) & (K Units)

Table 44. Latin America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2026-2031) & (K Units)

Table 45. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)

Table 46. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)

Table 47. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 48. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2020-2025) & (K Units)

Table 49. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2026-2031) & (K Units)

Table 50. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)

Table 51. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)

Table 52. Global PD-1 and PD-L1 Monoclonal Antibody Sales (K Units) by Type (2020-2025)

Table 53. Global PD-1 and PD-L1 Monoclonal Antibody Sales (K Units) by Type (2026-2031)

Table 54. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2020-2025)

Table 55. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2026-2031)

Table 56. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Type (2020-2025)

Table 57. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Type (2026-2031)

Table 58. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2020-2025)

Table 59. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2026-2031)

Table 60. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Type (2020-2025)

Table 61. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Type (2026-2031)

Table 62. Global PD-1 and PD-L1 Monoclonal Antibody Sales (K Units) by Application (2020-2025)

Table 63. Global PD-1 and PD-L1 Monoclonal Antibody Sales (K Units) by Application (2026-2031)

Table 64. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2020-2025)

Table 65. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2026-2031)

Table 66. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Application (2020-2025)

Table 67. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Application (2026-2031)

Table 68. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2020-2025)

Table 69. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2026-2031)

Table 70. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Application (2020-2025)

Table 71. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Application (2026-2031)

Table 72. Merk Company Information

Table 73. Merk Description and Business Overview

Table 74. Merk PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Merk PD-1 and PD-L1 Monoclonal Antibody Product

Table 76. Merk Recent Developments/Updates

Table 77. Bristol-Myers Squibb Company Company Information

Table 78. Bristol-Myers Squibb Company Description and Business Overview

Table 79. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product

Table 81. Bristol-Myers Squibb Company Recent Developments/Updates

Table 82. Roche Company Information

Table 83. Roche Description and Business Overview

Table 84. Roche PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. Roche PD-1 and PD-L1 Monoclonal Antibody Product

Table 86. Roche Recent Developments/Updates

Table 87. Pfizer Company Information

Table 88. Pfizer Description and Business Overview

Table 89. Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Pfizer PD-1 and PD-L1 Monoclonal Antibody Product

Table 91. Pfizer Recent Developments/Updates

Table 92. AstraZeneca Company Information

Table 93. AstraZeneca Description and Business Overview

Table 94. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 95. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product

Table 96. AstraZeneca Recent Developments/Updates

Table 97. Junshi Biosciences Company Information

Table 98. Junshi Biosciences Description and Business Overview

Table 99. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 100. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product

Table 101. Junshi Biosciences Recent Developments/Updates

Table 102. Innovent Company Information

Table 103. Innovent Description and Business Overview

Table 104. Innovent PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 105. Innovent PD-1 and PD-L1 Monoclonal Antibody Product

Table 106. Innovent Recent Developments/Updates

Table 107. Hengrui Company Information

Table 108. Hengrui Description and Business Overview

Table 109. Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 110. Hengrui PD-1 and PD-L1 Monoclonal Antibody Product

Table 111. Hengrui Recent Developments/Updates

Table 112. BeiGene Company Information

Table 113. BeiGene Description and Business Overview

Table 114. BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 115. BeiGene PD-1 and PD-L1 Monoclonal Antibody Product

Table 116. BeiGene Recent Developments/Updates

Table 117. Alphamab Oncology Company Information

Table 118. Alphamab Oncology Description and Business Overview

Table 119. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 120. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product

Table 121. Alphamab Oncology Recent Developments/Updates

Table 122. Cstone Company Information

Table 123. Cstone Description and Business Overview

Table 124. Cstone PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 125. Cstone PD-1 and PD-L1 Monoclonal Antibody Product

Table 126. Cstone Recent Developments/Updates

Table 127. Akeso Company Information

Table 128. Akeso Description and Business Overview

Table 129. Akeso PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 130. Akeso PD-1 and PD-L1 Monoclonal Antibody Product

Table 131. Akeso Recent Developments/Updates

Table 132. Henlius Biotech Company Information

Table 133. Henlius Biotech Description and Business Overview

Table 134. Henlius Biotech PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 135. Henlius Biotech PD-1 and PD-L1 Monoclonal Antibody Product

Table 136. Henlius Biotech Recent Developments/Updates

Table 137. Lepu Biopharma Company Information

Table 138. Lepu Biopharma Description and Business Overview

Table 139. Lepu Biopharma PD-1 and PD-L1 Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 140. Lepu Biopharma PD-1 and PD-L1 Monoclonal Antibody Product

Table 141. Lepu Biopharma Recent Developments/Updates

Table 142. Key Raw Materials Lists

Table 143. Raw Materials Key Suppliers Lists

Table 144. PD-1 and PD-L1 Monoclonal Antibody Distributors List

Table 145. PD-1 and PD-L1 Monoclonal Antibody Customers List

Table 146. PD-1 and PD-L1 Monoclonal Antibody Market Trends

Table 147. PD-1 and PD-L1 Monoclonal Antibody Market Drivers

Table 148. PD-1 and PD-L1 Monoclonal Antibody Market Challenges

Table 149. PD-1 and PD-L1 Monoclonal Antibody Market Restraints

Table 150. Research Programs/Design for This Report

Table 151. Key Data Information from Secondary Sources

Table 152. Key Data Information from Primary Sources

Table 153. Authors List of This Report

List of Figures

Figure 1. Product Picture of PD-1 and PD-L1 Monoclonal Antibody

Figure 2. Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Type: 2024 & 2031

Figure 4. PD-1 Product Picture

Figure 5. PD-L1 Product Picture

Figure 6. Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Product Name, (US$ Million) & (2020-2031)

Figure 7. Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Product Name: 2024 VS 2031

Figure 8. Pembrolizumab Product Picture

Figure 9. Nivolumab Product Picture

Figure 10. Cemiplimab Product Picture

Figure 11. Toripalimab Product Picture

Figure 12. Sintilimab Product Picture

Figure 13. Tislelizumab Product Picture

Figure 14. Camrelizumab Product Picture

Figure 15. Penpulimab Product Picture

Figure 16. Retifanlimab Product Picture

Figure 17. Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Dosage Strength, (US$ Million) & (2020-2031)

Figure 18. Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Dosage Strength: 2024 VS 2031

Figure 19. 100 mg / Vial Product Picture

Figure 20. 200 mg / Vial Product Picture

Figure 21. 240 mg / Vial Product Picture

Figure 22. 300 mg / Vial Product Picture

Figure 23. Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Application (2020-2031) & (US$ Million)

Figure 24. Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Application: 2024 & 2031

Figure 25. Solid Tumors

Figure 26. Blood-related Tumors

Figure 27. Global PD-1 and PD-L1 Monoclonal Antibody Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 28. Global PD-1 and PD-L1 Monoclonal Antibody Market Size (2020-2031) & (US$ Million)

Figure 29. Global PD-1 and PD-L1 Monoclonal Antibody Sales (2020-2031) & (K Units)

Figure 30. Global PD-1 and PD-L1 Monoclonal Antibody Average Price (US$/Unit) & (2020-2031)

Figure 31. PD-1 and PD-L1 Monoclonal Antibody Report Years Considered

Figure 32. PD-1 and PD-L1 Monoclonal Antibody Sales Share by Manufacturers in 2024

Figure 33. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Share by Manufacturers in 2024

Figure 34. Global 5 and 10 Largest PD-1 and PD-L1 Monoclonal Antibody Players: Market Share by Revenue in PD-1 and PD-L1 Monoclonal Antibody in 2024

Figure 35. PD-1 and PD-L1 Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 36. Global PD-1 and PD-L1 Monoclonal Antibody Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 37. North America PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2020-2031)

Figure 38. North America PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2020-2031)

Figure 39. U.S. PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Canada PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2020-2031)

Figure 42. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2020-2031)

Figure 43. Germany PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. France PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. U.K. PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Italy PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Russia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2020-2031)

Figure 49. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2020-2031)

Figure 50. China PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Japan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. South Korea PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. India PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Australia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Taiwan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Indonesia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Thailand PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Malaysia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. Philippines PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 60. Latin America PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2020-2031)

Figure 61. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2020-2031)

Figure 62. Mexico PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 63. Brazil PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 64. Argentina PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 65. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2020-2031)

Figure 66. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2020-2031)

Figure 67. Turkey PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 68. Saudi Arabia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 69. U.A.E PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 70. Global Sales Market Share of PD-1 and PD-L1 Monoclonal Antibody by Type (2020-2031)

Figure 71. Global Revenue Market Share of PD-1 and PD-L1 Monoclonal Antibody by Type (2020-2031)

Figure 72. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Type (2020-2031)

Figure 73. Global Sales Market Share of PD-1 and PD-L1 Monoclonal Antibody by Application (2020-2031)

Figure 74. Global Revenue Market Share of PD-1 and PD-L1 Monoclonal Antibody by Application (2020-2031)

Figure 75. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Application (2020-2031)

Figure 76. PD-1 and PD-L1 Monoclonal Antibody Value Chain

Figure 77. Channels of Distribution (Direct Vs Distribution)

Figure 78. Bottom-up and Top-down Approaches for This Report

Figure 79. Data Triangulation

Figure 80. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global PD 1 and PD L1 Inhibitor Market Research Report 2025

Global Monoclonal Antibodies Product Market Research Report 2024

Global Monoclonal Antibody for Multiple Myeloma Market Research Report 2024

Global Long Acting Monoclonal Antibodies Market Research Report 2024

Global Anti PD 1 MAb Market Insights Forecast to 2030

Global Pembrolizumab Market Research Report 2024

PD 1 and PD L1 Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Immune Checkpoint Agents Market Research Report 2025

Global PD 1 Inhibitor Market Research Report 2024

Pd 1 and Pd L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global PD 1 and PDL 1 Inhibitors Market Research Report 2025

Global Anti PD 1 Antibody Market Insights Forecast to 2030

Global PD 1 and PD L1 Immunotherapy Market Insights Forecast to 2030

Global Immune Checkpoint Blockers Market Research Report 2025

Global PDL1 Antibody Reagent Immunohistochemistry Market Research Report 2024

PD 1 PD L1 Inhibitors for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global ALK 1 Antibody Market Research Report 2024

PD L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Monoclonal Antibody Therapy for Treatment of ALL Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions